IBI303, a biosimilar to adalimumab developed by Chinese biopharmaceutical company Innovent Biologics, is comparable in safety and efficacy to the originator drug among patients with ankylosing spondylitis, according to data published in The Lancet Rheumatology.
“China approved adalimumab for the treatment of rheumatoid arthritis in 2010 and ankylosing spondylitis in 2013,” Huji Xu, MD, of Shanghai Changzheng Hospital and the Second Military Medical University, in Shanghai, and colleague wrote. “However, the cost of the standard dose regimen exceeds ¥15,000 (around U.S. $2,250) per month, which is well beyond the affordability of most Chinese patients, considering the cost is not covered by health insurance in China. Thus, the development of biosimilars as an alternative strategy to the high cost of adalimumab will make treatment more widely available to patients.”
Search Healio's robust listing of national and international medical meetings.
Tell us what you think about Healio.com »
Get the latest news and education delivered to your inbox
©2019 Healio All Rights Reserved.